SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
WEST LAFAYETTE, Ind., Dec. 01, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte’s SMDC EC1456 will be presented at the IASLC 17th World Conference on Lung Cancer on Wednesday, Dec. 7, at 2:30 P.M. CET. The conference will be held at the Messe Wien Exhibition & Congress Center in Vienna, Austria.
The presentation will be available on Endocyte’s website following presentation at the conference.
Presentation is as follows:
| Poster Presentation: | Phase 1 Dose Escalation, Safety and Pharmacokinetic Study of the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Patient Subset | ||
| When: | Wednesday, December 7th, 2:30 p.m. – 3:45 p.m. CET, Hall B | ||
| Track: | Advanced NSCLC | ||
| Presenter: | Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore | ||
About EC1456 and etarfolatide
EC1456 is an investigational therapeutic SMDC constructed of folic acid conjugated through a spacer and releasable linker system to a potent cytotoxic microtubule inhibitor, TubBH. The high affinity of the folic acid ligand for the FR allows for the active and specific targeting of EC1456 to FR-expressing cancer cells. The FR is highly expressed in several epithelial cancers (e.g. ovarian, NSCLC) but is expressed at low levels in most normal tissues.
Etarfolatide is an FR-targeted companion imaging agent being co-developed to characterize whole body FR expression in real time, to identify patients most likely to benefit from EC1456 therapy. EC1456 and etarfolatide are currently being evaluated in a phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
